RecruitingPhase 3NCT07059000
A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Kedrion S.p.A.
- Principal Investigator
- Mirella Calcinai, MDKedrion S.p.A.
- Intervention
- Kedrion IVIG 10%(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2025 – 2026
Study locations (27)
- University of Southern California, Los Angeles, California, United States
- East Carolina University, Greenville, North Carolina, United States
- Vseobecna Fakultni Nemocnice v Praze, Prague, Prague, Czechia
- Fakultni Nemocnice Brno, Brno, South Moravian, Czechia
- Onkologisches Zentrum Donauwörth Neudegger - Onkomedeor Onkologische Zentren, Donauwörth, Bavaria, Germany
- Universitätsklinikum Frankfurt, Frankfurt am Main, Hesse, Germany
- Azienda Ospedaliero - Universitaria Careggi, Florence, Florence, Italy
- Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara, Novara, Novara, Italy
- Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Trieste, Italy
- Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Torino, Turin, Italy
- AULSS 8 Berica - Ospedale San Bortolo Di Vicenza, Vicenza, Vicenza, Italy
- Coltea - Spital Clinic, Bucharest, București, Romania
- Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj, Romania
- Spitalul Filantropia - Craiova, Craiova, Dolj, Romania
- Univerzitetski Klinicki Centar Srbije, Belgrade, Serbia
- +12 more locations on ClinicalTrials.gov
Collaborators
ICON plc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07059000 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation